Background and purpose
In April 2016, following the preliminary analysis [1] and the production process validation, the Central IntraVenous Additive Services (CIVAS) has been completed and endowed of a robotic system for the compounding of non-toxic intravenous injectable drugs (IV). Nowadays, antiemetic drugs represent an essential anticancer support treatment in order to prevent nausea and vomiting induced by chemotherapy (CINV) and we thought that providing it as mini-bags ready for administration may results in a better efficiency of hospital workflow and increase in nurse time devoted to patient assistance.
The goal of this study is the evaluation of the reproducibility, the time and the dosage accuracy associated with the automated batches production of the CINV preventing IV therapy, in particular the 5HT3 inhibitors ondansentron and palonosetron.
12-weeks palonosetron and ondansetron automated production have been analyzed, evaluating the average dosage error and the average preparation time. All data have been elaborated through APOTECAmanager, the management software of the pharmacy IV production.
Material and methods
According to drugs stability, CIVAS produced: 12 palonosetron 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44 The production of IV bags of 5HT3 inhibitors can be excellently performed through robotic system compounding since the results of batches production shows an high process reproducibility, a reasonable average preparation time and an optimal accuracy.
Next steps will be the inclusion within the new automated and 
